An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and thymosin beta-4. The panel rejected emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may aid treatment of antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for expanded access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how regulators view custom-mixed peptide therapies, which have drawn increasing interest from patients seeking alternatives to standard drugs. Researchers say peptide treatments could alter approaches to resistant infections, though concerns about consistency persist. The committee's endorsement of six peptides paves the way for more widespread prescribing, even as skeptics warn of long-term evidence. Industry analysts note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, highlights the FDA's cautious stance on certain peptide candidates.